Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to "Strong-Buy" at Truist Financial

Truist Financial upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

TEVA has been the subject of several other research reports. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $24.50.

Teva Pharmaceutical Industries Trading Down 4.3%

Shares of Teva Pharmaceutical Industries stock traded down $0.76 during trading on Tuesday, hitting $16.77. The stock had a trading volume of 19,852,269 shares, compared to its average volume of 10,116,307. The stock has a 50 day simple moving average of $15.52 and a 200 day simple moving average of $17.36. The company has a market capitalization of $19.01 billion, a PE ratio of -11.57, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.48 EPS. On average, research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after buying an additional 22,044,407 shares during the last quarter. FMR LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Duquesne Family Office LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after buying an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 472.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after buying an additional 5,186,592 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Teva Pharmaceutical Industries by 416.0% during the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after buying an additional 4,824,247 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.